Physician profile
Binit Shah
NPI 1073779476
$16,751.59
in general payments reported to CMS, 2019-2025
16 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,399 · 2021: $588 · 2022: $878 · 2023: $273 · 2024: $5,302 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $1,313 · Travel and Lodging: $73.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $1,313.34 |
| Travel and Lodging | $73.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $5,541.40 | 2019 | |
| Boston Scientific Corporation | $3,829.73 | 2019-2024 | |
| Abbvie INC. | $3,247.11 | 2021-2025 | |
| Abbott Laboratories | $2,409.94 | 2024 | Infinity |
| Spinal Simplicity, LLC | $878.01 | 2022 | |
| Neurocrine Biosciences, INC. | $553.84 | 2023-2025 | Ingrezza |
| Medtronic, INC. | $127.44 | 2021-2024 | Percept PC Brainsense |
| Nalu Medical, INC. | $41.96 | 2021 | |
| Tanabe Pharma America, INC. | $37.23 | 2025 | Radicava |
| Acadia Pharmaceuticals INC | $30.20 | 2019 | |
| Merz North America, INC. | $18.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.11 | 2023 | Invega Sustenna |
| Biohaven Pharmaceuticals, INC. | $17.71 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.